Intravitreal aflibercept and ranibizumab injections for type 3 neovascularization
Conclusion: There was no difference between the aflibercept and ranibizumab treatments in terms of visual acuity improvement after 12 months in patients with Type 3 neovascularization. However, geographic atrophy developed more frequently in the aflibercept-treated group. (Source: RETINA)
Source: RETINA - October 25, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Long-term outcomes of ranibizumab treatment of myopic choroidal neovascularization in east-asian patients from the radiance study
Purpose: To evaluate long-term efficacy and safety of ranibizumab for treatment of myopic choroidal neovascularization (mCNV) in clinical practice. Methods: Noninterventional, retrospective cohort study of East-Asian patients previously treated with ranibizumab during the RADIANCE trial. Forty-one patients who completed the RADIANCE trial were followed-up for up to 48 months (post-RADIANCE observation period). Outcome measures were best-corrected visual acuity changes from baseline (assessed at RADIANCE trial initiation), mCNV recurrences, and ocular adverse events. Results: Mean visual gain from baseline best-corr...
Source: RETINA - October 25, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Using Post-market Utilisation Analysis to Support Medicines Pricing Policy: An Australian Case Study of Aflibercept and Ranibizumab Use
ConclusionsContrary to clinical trial protocols, post-market utilisation research for ranibizumab and aflibercept demonstrates equivalent use in practice in terms of dose frequency, and the demographic and clinical characteristics of initiators. This supports Australia ’s decision to pay the same price for each rather than giving a premium to aflibercept. Many other countries are likely overpaying for aflibercept if their utilization patterns are similar to Australia’s, and could benefit from incorporating routine utilisation assessment. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - October 25, 2018 Category: Health Management Source Type: research

One-step solid-oil-water emulsion for sustained bioactive ranibizumab release
. (Source: Expert Opinion on Drug Delivery)
Source: Expert Opinion on Drug Delivery - October 25, 2018 Category: Drugs & Pharmacology Authors: Hui Yee Chua Yuan Siang Lui Ramya Bhuthalingam Rupesh Agrawal Tina Wong Peter Rainer Preiser Subbu Venkatraman Source Type: research

Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12 ‐month results from a randomized controlled study
Clinical&Experimental Ophthalmology,Volume 0, Issue ja, -Not available-. (Source: Clinical and Experimental Ophthalmology)
Source: Clinical and Experimental Ophthalmology - October 22, 2018 Category: Opthalmology Authors: Songshan Li, Xiaoyan Ding, Limei Sun, Xiujuan Zhao, Aiyuan Zhang, Cancan Lyu, Bingqian Liu, Junyan Zhang, Chenjin Jin, Lin Lu Source Type: research

Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
CONCLUSIONS: Anti-VEGF drugs are effective at improving vision in people with DMO with three to four in every 10 people likely to experience an improvement of 3 or more lines VA at one year. Aflibercept may confer some advantage over ranibizumab and bevacizumab in people with DMO at one year in visual and anatomic terms but it is unclear whether this applies to the long-term. There is a need for more evidence on the long-term (greater than two years) comparative effects of these anti-VEGF agents. Evidence from RCTs may not apply to real-world practice, where people in need of antiangiogenic treatment are often under-treate...
Source: Cochrane Database of Systematic Reviews - October 16, 2018 Category: General Medicine Authors: Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E Tags: Cochrane Database Syst Rev Source Type: research

Treatment of Punctate Inner Choroidopathy with Choroidal Neovascularization Using Corticosteroid and Intravitreal Ranibizumab.
Conclusion: Both corticosteroid-ranibizumab treatment and ranibizumab monotherapy could significantly improve the vision of PIC patients with CNV. Combined corticosteroid and intravitreal ranibizumab treatment appeared to reduce CNV recurrence and development of new PIC lesions compared with ranibizumab monotherapy. PMID: 30302336 [PubMed - in process] (Source: Biomed Res)
Source: Biomed Res - October 12, 2018 Category: Research Authors: Wu W, Li S, Xu H, Liu Y, Wang Y, Lai TYY, Yin ZQ Tags: Biomed Res Int Source Type: research

[Treatment reality with ranibizumab in clinical routine use for patients with diabetic macular edema : 1 ‑year results of the German POLARIS cohort].
This article describes the results of the German POLARIS population. The study was conducted in 8 European countries from October 2012 to January 2015. RESULTS: In Germany 220 patients were included in the study. Visual acuity improved by 4.3 letters within the first 3 months of treatment. At 12 months, visual acuity increased on average by 4.1 (SD ± 12.4) letters (approximately 1 line) for 168 patients enrolled in the efficacy analysis. Patients received an average of 4.5 (SD ± 1.9) injections, 10.3 (SD ± 6.3) visual acuity tests and 3.3 (SD &plusm...
Source: Der Ophthalmologe - October 10, 2018 Category: Opthalmology Authors: Ulbig M, Höh H, Schmickler S, Wolf A, Dimopoulos S, Lorenz K, Bauer-Steinhusen U, Wiedemann P, POLARIS-Studiengruppe Tags: Ophthalmologe Source Type: research

Age-related macular degeneration
Publication date: 29 September–5 October 2018Source: The Lancet, Volume 392, Issue 10153Author(s): Paul Mitchell, Gerald Liew, Bamini Gopinath, Tien Y WongSummaryAge-related macular degeneration is a leading cause of visual impairment and severe vision loss. Clinically, it is classified as early-stage (medium-sized drusen and retinal pigmentary changes) to late-stage (neovascular and atrophic). Age-related macular degeneration is a multifactorial disorder, with dysregulation in the complement, lipid, angiogenic, inflammatory, and extracellular matrix pathways implicated in its pathogenesis. More than 50 genetic susce...
Source: The Lancet - October 5, 2018 Category: General Medicine Source Type: research

Intravitreal Ranibizumab Therapy for Diabetic Macular Edema in Routine Practice: Two-Year Real-Life Data from a Non-interventional, Multicenter Study in Germany
ConclusionUnder-treatment is a major problem of DME anti- vascular endothelial growth factor therapy under real life conditions. Despite fewer injections given compared to randomised controlled trials with a consequently reduced overall mean visual gain, a profound functional improvement ( ≥ 15 letters) was achieved over 2 years in 23.5% of eyes with DME.Trial Registration NumberNCT02194803, ClinicalTrials.gov.FundingNovartis Pharma GmbH, Nuremberg, Germany. (Source: Diabetes Therapy)
Source: Diabetes Therapy - October 4, 2018 Category: Endocrinology Source Type: research

CONTAMINATION OF ANTI-VEGF DRUGS FOR INTRAVITREAL INJECTION: How Do Repackaging and Newly Developed Syringes Affect the Amount of Silicone Oil Droplets and Protein Aggregates?
Conclusion: All three tested agents are available in similar quality regarding particulate purity and silicone oil microdroplet count. Repackaging can have a major impact on the quality. (Source: RETINA)
Source: RETINA - October 1, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Disease activity after development of large subretinal hemorrhage in polypoidal choroidal vasculopathy
Purpose: To investigate changes in disease activity after a large subretinal hemorrhage in polypoidal choroidal vasculopathy. Methods: Fifty-two polypoidal choroidal vasculopathy eyes with large subretinal hemorrhage (at initial presentation [n = 33, Group 1] or developed during follow-up [n = 19, Group 2]) were enrolled. Thirty polypoidal choroidal vasculopathy eyes without subretinal hemorrhage were enrolled as controls. All subretinal hemorrhages were treated with pneumatic displacement. Other active lesions were treated with intravitreal ranibizumab on an as-needed basis. Injection-free period, 1-year injection nu...
Source: RETINA - October 1, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Ultrasonographic findings in the vitreous of patients with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections
Conclusion: These preliminary results indicate a proportional increase in ultrasonographic reflectivity of vitreous gel with the number of injections. (Source: RETINA)
Source: RETINA - October 1, 2018 Category: Opthalmology Tags: Original Study Source Type: research

RANIBIZUMAB AND AFLIBERCEPT FOR THE TREATMENT OF PIGMENT EPITHELIAL DETACHMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Data from an Observational Study
Conclusion: Eyes with neovascular age-related macular degeneration and RPED showed significant functional and anatomical responses after 6 months of intravitreal anti–vascular endothelial growth factor injections. However, we found no significant difference in anatomical response or change in visual acuity between eyes treated with ranibizumab compared with aflibercept. Larger, prospectively designed, randomized studies with longer term follow-up may identify a difference between the two drugs that we did not detect. (Source: RETINA)
Source: RETINA - October 1, 2018 Category: Opthalmology Tags: Original Study Source Type: research

CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB: DRCR.net Protocol I 5-Year Report
Conclusion: Individuals receiving ranibizumab therapy for diabetic macular edema may have favorable changes in DR severity throughout a 5-year period concomitant with sequential reduction in anti–vascular endothelial growth factor therapy. (Source: RETINA)
Source: RETINA - October 1, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Choroidal thickness changes in non-treated acute and ranibizumab-treated chronic central serous chorioretinopathy
To evaluate the changes in subfoveal retinal, and choroidal thicknesses (CT) in the non-treated acute and the ranibizumab-treated chronic central serous chorioretinopathy (CSCR) patients. This retrospective study included 32 eyes of 32 consecutive patients with CSCR. There were 12 patients who presented with a spontaneous resolution of CSCR (Group 1) and 20 patients who were treated with ranibizumab for persistent subretinal fluid (SRF) (Group 2). Optical coherence tomography (OCT) imaging of subfoveal retinal thickness and enhanced depth imaging OCT of CT at subfoveal; at nasal and temporal 500 μm (T500); at nasal a...
Source: Medicine - October 1, 2018 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation
This study included laser-naive PDR patients that required PRP. Eyes were randomly and prospectively assigned to receive IVR or IVR combined with PASCAL or EDTRS. PRP was performed at baseline in 1 (PASCAL) or 2 (ETDRS) sessions. In eyes with macular edema, macular short pulse grid laser was associated with IVR at baseline and IVR was repeated monthly or quarterly if neovascularization was detected on angiography. Comprehensive ophthalmological evaluations, including SD-OCT, were performed at baseline and every 4  weeks after treatment. Full-field electroretinography (ERG: extended ISCEV standard) was performed at bas...
Source: Documenta Ophthalmologica - October 1, 2018 Category: Opthalmology Source Type: research

Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy
This randomized clinical trial reports that 5-year visual acuity results were similar in patients treated with panretinal photocoagulation and ranibizumab for proliferative diabetic retinopathy. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - October 1, 2018 Category: Opthalmology Source Type: research

Bevacizumab dosing every 2 weeks for neovascular age-related macular degeneration refractory to monthly dosing
Conclusion:This study demonstrates that biweekly bevacizumab injections are effective in nearly one-quarter of nAMD non-responders with no adverse events reported. Switching earlier, rather than later, to this low cost modality may be of benefit for a portion of non-responders to conventional treatment. (Source: Japanese Journal of Ophthalmology)
Source: Japanese Journal of Ophthalmology - September 29, 2018 Category: Opthalmology Source Type: research

Comparison of the effect of ranibizumab and dexamethasone implant on serous retinal detachment in diabetic macular edema.
Authors: Demircan A, Ozkaya A, Alkin Z, Kemer B, Yesilkaya C, Demir G Abstract PURPOSE: To compare the efficacy of intravitreal ranibizumab (IVR) and intravitreal dexamethasone implant (IDI) on neurosensory retinal detachment (SRD) associated with diabetic macular edema (DME) in the early treatment period. METHODS: This was a retrospective, interventional, case-control study. After three monthly loading doses of IVR or an initial IDI injection, the changes in best-corrected visual acuity (BCVA), central macular thickness (CMT) on OCT, and presence and height of SRD were evaluated. RESULTS: The IVR and IDI g...
Source: Journal Francais d Ophtalmologie - September 16, 2018 Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research

Effect of ranibizumab on levels of IL-6 and VEGF in peripheral blood and aqueous humor of glaucoma rat model and association of IL-6 and VEGF with optic nerve damage.
This study aims to investigate the effect of intravitreal injection of ranibizumab on glaucoma rat model and its effect on optic nerve injury. A total of 125 SD rats were used to establish glaucoma models. Of them, 80 well-established model were selected, 40 of which received intravitreal injections of ranibizumab and were assigned to the observation group. The remaining 40 received no drug and were assigned to the control group. After rats were sacrificed at the time-points, the retina was harvested. Numbers of retinal ganglion cells (RGCs) were counted under a fluorescence microscope. In the meantime, levels of interleuk...
Source: Experimental and Therapeutic Medicine - September 14, 2018 Category: General Medicine Tags: Exp Ther Med Source Type: research

Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation
This study included laser-naive PDR patients that required PRP. Eyes were randomly and prospectively assigned to receive IVR or IVR combined with PASCAL or EDTRS. PRP was performed at baseline in 1 (PASCAL) or 2 (ETDRS) sessions. In eyes with macular edema, macular short pulse grid laser was associated with IVR at baseline and IVR was repeated monthly or quarterly if neovascularization was detected on angiography. Comprehensive ophthalmological evaluations, including SD-OCT, were performed at baseline and every 4  weeks after treatment. Full-field electroretinography (ERG: extended ISCEV standard) was performed at bas...
Source: Documenta Ophthalmologica - September 12, 2018 Category: Opthalmology Source Type: research

Effect of mitochondrial haplogroups on ranibizumab response in neovascular age ‐related macular degeneration patients: a pilot study
Acta Ophthalmologica, EarlyView. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - September 11, 2018 Category: Opthalmology Authors: Olivia Esteban , Francisco J. Ascaso , Javier Mateo , Tania Calvo , Julio Montoya , Eduardo Ruiz ‐Pesini Source Type: research

Choroidal blood flow after the first intravitreal ranibizumab injection in neovascular age ‐related macular degeneration patients
Acta Ophthalmologica, EarlyView. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - September 11, 2018 Category: Opthalmology Authors: Benjamin Mottet , Florent Aptel , Martial Henri Geiser , Ruxandra Hera , Thierry Zhou , Ahmed Almanjoumi , Viviane Vinh , Christophe Chiquet Source Type: research

Effect of intravitreal dexamethasone on macular edema in von Hippel-Lindau disease assessed using swept-source optical coherence tomography: a case report
ConclusionsIn our experience, intravitreal dexamethasone administration has proven to be a useful tool for reducing retinal hemangioblastoma-related macular edema in von Hippel-Lindau disease and may be considered a potentially valuable treatment that can be used in combination with other therapies. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - September 6, 2018 Category: General Medicine Source Type: research

Retinopathy of prematurity after intravitreal ranibizumab monotherapy
Publication date: August 2018Source: Journal of American Association for Pediatric Ophthalmology and Strabismus, Volume 22, Issue 4Author(s): Mariana A. Flores Pimentel, Alejandra G. de Alba Campomanes (Source: Journal of American Association for Pediatric Ophthalmology and Strabismus)
Source: Journal of American Association for Pediatric Ophthalmology and Strabismus - September 4, 2018 Category: Opthalmology Source Type: research

Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen.
CONCLUSION: MA growth rates were associated with ocular factors in the study eyes and the fellow eyes but not with the drug or the number of injections within this variable dosing regimen. PMID: 30166328 [PubMed - as supplied by publisher] (Source: The British Journal of Ophthalmology)
Source: The British Journal of Ophthalmology - August 30, 2018 Category: Opthalmology Authors: Mantel I, Zola M, De Massougnes S, Dirani A, Bergin C Tags: Br J Ophthalmol Source Type: research

Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan
Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan, Published online: 29 August 2018; doi:10.1038/s41433-018-0192-2Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan (Source: Eye)
Source: Eye - August 29, 2018 Category: Opthalmology Authors: Kyoko Ohno-Matsui Makoto Suzaki Rie Teshima Nina Okami Source Type: research

Changes in plasma vascular endothelial growth factor level after intravitreal injection of bevacizumab, aflibercept, or ranibizumab for diabetic macular edema
Purpose: The aim of this study was to investigate the changes in plasma vascular endothelial growth factor (VEGF) level depending on the severity of diabetic retinopathy (DR) or diabetic macular edema (DME) and after intravitreal injection of bevacizumab, aflibercept, or ranibizumab for treatment of DME. Methods: Plasma VEGF level was evaluated in 72 patients with DR and changes were measured in 42 patients with DME receiving intravitreal injections of bevacizumab, aflibercept, or ranibizumab at the initial injection. Results: There were no correlations between plasma VEGF level and the severity of DME or DR. Basel...
Source: RETINA - August 23, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Impact of long-term intravitreal anti–vascular endothelial growth factor on preexisting microstructural alterations in diabetic macular edema
Purpose: Evaluation of the influence of long-term intravitreal anti–vascular endothelial growth factor treatment on preexisting retinal microstructural alterations in patients with diabetic macular edema. Methods: Eyes with diabetic macular edema and a history of ≥ 20 intravitreal anti–vascular endothelial growth factor (aflibercept and/or ranibizumab) injections were included in this retrospective study. Primary outcome was the extent of disorganization of retinal inner layers, alterations at the outer plexiform layer/Henle fiber layer junction, disruption of external limiting membrane/ellipsoid zone, ...
Source: RETINA - August 23, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Successful management of peripapillary choroidal neovascular membrane secondary to idiopathic intracranial hypertension with intravitreal ranibizumab
Nitin Kumar, Basavraj Tigari, Mohit Dogra, Ramandeep SinghIndian Journal of Ophthalmology 2018 66(9):1358-1360 Idiopathic intracranial hypertension (IIH) is a common cause of papilledema in young females and causes headache with transient visual loss. Severe visual loss occurs due to optic atrophy or peripapillary choroidal neovascular membrane (PCNVM). PCNVM in IIH has an incidence of 0.5% with a benign course in the majority of patients. Intravitreal Anti-vascular endothelial growth factor agents have anecdotally been used to manage these patients, with complete resolution reported in all cases after a single inject...
Source: Indian Journal of Ophthalmology - August 20, 2018 Category: Opthalmology Authors: Nitin Kumar Basavraj Tigari Mohit Dogra Ramandeep Singh Source Type: research

Combination of bevacizumab and photodynamic therapy vs. bevacizumab monotherapy for the treatment of wet age-related macular degeneration: A meta-analysis of randomized controlled trials.
Authors: Wei Q, Liu J, Liu Q, Ren C, Cai W, Liang X, Wen J, Yu J Abstract The purpose of this meta-analysis was to compare the efficacy and safety of the combination of bevacizumab and photodynamic therapy (PDT) with bevacizumab monotherapy for the treatment of age-related macular degeneration (AMD). Patients with active choroidal neovascularization (CNV) secondary to AMD were included in the present study. The treatment group included patients treated with a combination of bevacizumab and PDT and patients treated with bevacizumab monotherapy. Only randomized controlled trials (RCTs) were included in the analysis. ...
Source: Experimental and Therapeutic Medicine - August 19, 2018 Category: General Medicine Tags: Exp Ther Med Source Type: research

Corrigendum to "Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab".
Corrigendum to "Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab". J Ophthalmol. 2018;2018:9171269 Authors: Tran THC, Dumas S, Coscas F Abstract [This corrects the article DOI: 10.1155/2017/8984313.]. PMID: 30116636 [PubMed - in process] (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - August 19, 2018 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Extended Injection Intervals after Switching from Ranibizumab to Aflibercept in Macular Edema due to Central Retinal Vein Occlusion.
Conclusion: In case of insufficient response or frequent recurrences of ME due to CRVO in patients treated with ranibizumab on a TAE basis, switching to aflibercept could allow extending treatment intervals, which could reduce the injection burden for these patients. PMID: 30116635 [PubMed] (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - August 19, 2018 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Neovascular Age ‐Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect
CPT: Pharmacometrics&Systems Pharmacology, EarlyView. (Source: CPT: Pharmacometrics and Systems Pharmacology)
Source: CPT: Pharmacometrics and Systems Pharmacology - August 16, 2018 Category: Drugs & Pharmacology Authors: Zufar Mulyukov , Sebastian Weber , Etienne Pigeolet , Andreas Clemens , Thorsten Lehr , Amy Racine Source Type: research

Choroidal neovascularization due to choroidal osteoma treated with anti-vascular endothelial growth factor therapy: An optical coherence tomography angiography study.
CONCLUSION: Optical coherence tomography angiography seems to be a useful tool in visualizing and distinguishing vascular networks of choroidal osteoma and of choroidal neovascularization secondary to choroidal osteoma better than fluorescein angiography. PMID: 30101614 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - August 13, 2018 Category: Opthalmology Authors: Furino C, Di Antonio L, Grassi MO, Rispoli M, Reibaldi M, Niro A, Alessio G Tags: Eur J Ophthalmol Source Type: research

Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema with Serous Retinal Detachment.
Authors: Kaya M, Karahan E, Ozturk T, Kocak N, Kaynak S Abstract PURPOSE: To evaluate the effectiveness of intravitreal injection of ranibizumab (IVR) in treating diabetic macular edema (DME) with serous retinal detachment (SRD) based on spectral domain optical coherence tomography (SD-OCT) patterns. METHODS: One hundred thirty-four eyes of 134 patients with DME who underwent SD-OCT evaluation were included in this study. We retrospectively analyzed the medical records of patients who received IVR for the treatment of DME. Their eyes were classified into three groups according to the following SD-OCT features: ...
Source: Korean Journal of Ophthalmology : KJO - August 11, 2018 Category: Opthalmology Tags: Korean J Ophthalmol Source Type: research

Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells.
CONCLUSIONS: Clinical dosages of ranibizumab, bevacizumab, or aflibercept do not induce significant cytotoxicity in senescent RPE cells. PMID: 30091312 [PubMed - in process] (Source: Korean Journal of Ophthalmology : KJO)
Source: Korean Journal of Ophthalmology : KJO - August 11, 2018 Category: Opthalmology Tags: Korean J Ophthalmol Source Type: research

Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study.
Abstract BACKGROUND/AIM: We previously reported that ranibizumab performed better on visual prognosis than photodynamic therapy (PDT) in a Ranibizumab (Lucentis) And Photodynamic Therapy On Polypoidal choroidal vasculopathy (LAPTOP) study. To determine if the first-choice treatment, either PDT or intravitreal ranibizumab, has a long-term effect in patients with polypoidal choroidal vasculopathy (PCV). METHODS: We reviewed medical records of patients randomised to either PDT (29 eyes) or ranibizumab (27 eyes) from July 2009 to June 2011 in LAPTOP study. Retreatment or switching to other treatments were at the ...
Source: The British Journal of Ophthalmology - August 4, 2018 Category: Opthalmology Authors: Miyamoto N, Mandai M, Oishi A, Nakai S, Honda S, Hirashima T, Oh H, Matsumoto Y, Uenishi M, Kurimoto Y Tags: Br J Ophthalmol Source Type: research

Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: A systematic review and network meta-analysis.
Abstract INTRODUCTION: Anti-vascular endothelial growth factor (VEGF) therapy has become the most commonly used treatment for macular edema secondary to retinal vein occlusion (RVO). Although its superior efficacy as compared to other interventions has been proven, there is a lack of evidence for relative efficacy among anti-VEGF drugs. Areas covered: This work systematically reviewed and compared the efficacy of intravitreal bevacizumab, ranibizumab, and aflibercept for treating macular edema due to RVO. PubMed, EMBASE, and the Cochrane Library were searched from their inception until October 2017. Eleven randomi...
Source: Pharmacological Reviews - August 2, 2018 Category: Drugs & Pharmacology Authors: Sangroongruangsri S, Ratanapakorn T, Wu O, Anothaisintawee T, Chaikledkaew U Tags: Expert Rev Clin Pharmacol Source Type: research

EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION DUE TO UNCOMMON CAUSE: Twelve-Month Results of the MINERVA Study
Purpose: To evaluate the efficacy and safety of ranibizumab 0.5 mg in adult patients with choroidal neovascularization because of an uncommon cause enrolled in the 12-month MINERVA study. Methods: In this Phase III, double-masked study, adult (≥18 years) patients (N = 178) were randomized 2:1 to receive either ranibizumab (n = 119) or sham (n = 59) at baseline and, if needed, at Month 1 and open-label individualized ranibizumab from Month 2. Best-corrected visual acuity change from baseline to Month 2 (primary endpoint) and Month 12, treatment exposure, and safety over 12 months were reported. Subgroup analysis was...
Source: RETINA - August 1, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Predictors of one-year visual outcomes after anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration
Purpose: To determine predictors of best-corrected visual acuity (BCVA) outcomes 1 year after ranibizumab or bevacizumab treatment for neovascular age-related macular degeneration, within the French Study Group Avastin versus Lucentis for neovascular age-related macular degeneration (GEFAL). Methods: Patients aged ≥50 years presenting subfoveal neovascular age-related macular degeneration were randomized to receive ranibizumab or bevacizumab (3 monthly intravitreal injections followed by an as-needed regimen). The main outcome measures were BCVA and its change from baseline at 1 year. Variables with a P value (Source: RETINA)
Source: RETINA - August 1, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Time course of changes in metamorphopsia following intravitreal ranibizumab injection for branch retinal vein occlusion
Purpose: To evaluate the effects of intravitreal ranibizumab injection (IVR) on metamorphopsia in patients with branch retinal vein occlusion (BRVO) and to assess the relationship between retinal microstructure and metamorphopsia. Methods: Subjects were 39 eyes of 39 patients with branch retinal vein occlusion. The severity of metamorphopsia was quantified using the M-CHARTS before and 1, 2, 3, 4, 5, and 6 months after treatment. Based on optical coherence tomography (OCT) images, we assessed central retinal thickness (CRT) and status of the external limiting membrane (ELM) and ellipsoid zone (EZ). The association bet...
Source: RETINA - August 1, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Short-term outcomes after intravitreal injections of conbercept versus ranibizumab for the treatment of retinopathy of prematurity
Conclusion: Both conbercept and ranibizumab are effective choice for the treatment of ROP. Conbercept is a novel effective treatment strategy for ROP providing a new treatment option for ophthalmologists. (Source: RETINA)
Source: RETINA - August 1, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study
ConclusionsThe rates of SAEs in both groups were low. The IVB and IVR treatments were not associated with significant risks of mortality, ATE, and non-fatal HF.Trial RegistrationThai Clinical Trial Registry identifier TCTR20141002001. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 1, 2018 Category: Drugs & Pharmacology Source Type: research

Understanding Variation in Response to Anti –Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration
A dozen years ago, the world changed for patients with neovascular age-related macular degeneration (nAMD) because of the introduction of the anti –vascular endothelial growth factor therapy (VEGF) agents ranibizumab and bevacizumab. For the first time, treatments were available that not only prevented loss of visual acuity but also improved vision for most patients. The outcomes found through 1 to 2 years of treatment were in stark contrast to the dismal course of untreated eyes and eyes treated with the modestly beneficial treatments available before 2005 (thermal laser, photodynamic therapy with verteporfin, or in...
Source: JAMA Ophthalmology - August 1, 2018 Category: Opthalmology Source Type: research